Europe Neurostimulation Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Europe Neurostimulation Devices Market Report is Segmented by Technology (Internal Neuromodulation [Spinal Cord Stimulation (SCS) and More] and External Neuromodulation), Application (Pain Management, Parkinson's Disease, Epilepsy, and More), End-User (Hospitals, and More), and Geography (Germany, United Kingdom, and More). The Market Forecasts are Provided in Terms of Value (USD).

Europe Neurostimulation Devices Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Europe Neurostimulation Devices Market with other markets in Healthcare Industry

Europe Neurostimulation Devices Market Analysis by Mordor Intelligence

The Europe Neurostimulation Devices market size stands at USD 2.79 billion in 2025 and is forecast to reach USD 4.76 billion by 2030, translating into an 11.28% CAGR. Demographic aging, a rising neurological disease burden, and steady regulatory support nurture a demand up-curve for sophisticated neuromodulation options. Continuous engineering advances—especially AI-enabled closed-loop systems—sharpen therapeutic precision and widen the addressable patient pool. At the same time, non-invasive alternatives win mindshare by lowering surgical risk, shortening recovery, and increasing adoption in outpatient and home settings. Intensifying vendor consolidation, led by Globus Medical’s acquisition of Nevro, signals a strategic race to command platform breadth and data science capabilities. However, Europe-specific supply-chain checks on rare-earth elements and extended EU-MDR review cycles add cost and scheduling friction that firms must navigate to preserve growth momentum.

Key Report Takeaways

  • By technology, internal neuromodulation led with 71.77% revenue share in 2024; external neuromodulation is projected to expand at 11.98% CAGR through 2030.  
  • By application, pain management accounted for 39.98% share of the Europe Neurostimulation Devices market size in 2024, while epilepsy is forecast to grow at 12.03% CAGR through 2030.  
  • By end-user, hospitals captured 47.87% share in 2024; home-care is set to grow at 12.11% CAGR to 2030.  
  • By geography, Germany held 29.91% share in 2024, whereas France is expected to record the fastest 12.32% CAGR by 2030.  

Segment Analysis

By Technology: External Momentum Upshifts as AI Matures

Internal neuromodulation commanded 71.77% of Europe Neurostimulation Devices market share in 2024, reflecting three decades of clinical routine and reimbursement familiarity. Yet external modalities trailblazed an 11.98% CAGR through 2030, propelled by next-generation rTMS platforms that deliver 10,000 pulses in under four minutes, trim session counts, and present minimal contraindications. The Europe Neurostimulation Devices market size for external modalities is expected to nearly double, helped by cloud-linked TMS headsets that document outcomes in payers’ preferred data formats. Rotating-coil multi-locus systems, now piloted in Germany, permit instantaneous cortical focus changes, improving efficacy for comorbid depression and insomnia.  

Internal platforms are hardly static. Closed-loop SCS leveraging ECAP feedback maintains durable pain relief at 12 months, anchoring replacement cycles that underpin manufacturer annuity revenue. Adaptive DBS expands beyond Parkinson’s into severe addiction use-cases under the Brain-PACER study in Cambridge, projecting new adoption curves once early clinical endpoints read out. Meanwhile, sacral and gastric stimulators continue serving niche bowel-motility disorders, reinforcing the technology’s multi-organ versatility.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Application: Pain Supremacy Faces Epilepsy Upswing

Pain indications represented 39.98% of the Europe Neurostimulation Devices market in 2024 as SCS, DRG stimulation, and peripheral nerve platforms secured cost-utility endorsements from major payers. Nonetheless, epilepsy emerges as the fastest mover at a 12.03% CAGR, buoyed by AI-enabled seizure prediction and vagus nerve stimulators that can trigger pre-emptive pulses. The Europe Neurostimulation Devices market size for epilepsy therapy lines is forecast to cross USD 1 billion by 2030, marking a material diversification of revenue mixes.  

Complementary demand drivers include adaptive DBS for Parkinson’s, high-frequency gastric pacing for obesity trials, and TMS for major depressive disorder. Multi-therapy convergence—where one implant treats pain and movement disorders via firmware upgrades—could unlock synergistic reimbursement codes, smoothing hospital procurement cycles.

By End-User: Hospital Core, Home-Care Surge

Hospitals retained 47.87% revenue share in 2024 because complex implant surgeries, MRI scans, and intra-operative programming still require specialized theatres and imaging suites. Ambulatory surgery centers now compete on same-day discharge convenience, nibbling at select volume bundles like DRG implants. In parallel, the home-care category’s 12.11% CAGR underscores patient demand for self-managed, non-invasive sessions. Home-approved TMS hoods and app-guided TENS devices extend physician oversight via encrypted telemetry, satisfying payer conditions for outcome documentation.  

The Europe Neurostimulation Devices market share expansion in home-care is further aided by national telehealth reimbursement codes adopted during the pandemic. Rapid-charge lithium polymer batteries and wireless firmware updates reduce maintenance visits, aligning with chronic-care funding models that emphasize out-of-hospital cost containment.

Europe Neurostimulation Devices Market: Market Share by End-User
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

Germany’s 29.91% stake stems from universal statutory coverage, an organized sickness-fund network, and the Digital Health Care Act, which fast-tracks the listing of connected devices. Manufacturers leverage Germany as a launch pad because early DiGA approvals translate into pan-EU credibility. France, advancing at a 12.32% CAGR, blends generous pain-therapy reimbursements with an agile clinical-trial ecosystem centered on Paris and Lyon. That mix attracts venture-backed neurotech SMEs keen to secure CE evidence in a single-payer environment.  

The United Kingdom preserves strategic relevance despite post-Brexit regulatory bifurcation. The MHRA’s fast-track pathway for “innovative implantables” and NHS England’s MedTech Funding Mandate give local trials global visibility. Southern markets like Italy and Spain accelerate adoption as demographic aging climbs and EU recovery funds modernize neurology infrastructure. Eastern Europe, though budget-constrained, shows rising procurement under cross-border reimbursement frameworks, opening second-wave growth for value-oriented device configurations.  

Nordic nations integrate neuromodulation into national e-referral portals, enabling seamless prescription of home-based TENS and TMS kits. Meanwhile, Ireland and Benelux benefit from multinational manufacturing hubs that shorten supply lead times. Collectively, these regional nuances require adaptive go-to-market playbooks but sustain the overall trajectory of the Europe Neurostimulation Devices market.

Competitive Landscape

Industry concentration remains moderate. Medtronic, Boston Scientific, Abbott, and LivaNova command the top tier, yet their combined slice stays below the 60% threshold, leaving room for midsize specialists. Globus Medical’s USD 250 million purchase of Nevro in April 2025 integrates high-frequency SCS and AI analytics into a spine-implant powerhouse, signaling a premium on data-rich pain platforms. Boston Scientific’s new DBS software, which secures CE clearance for symptom-specific segmentation, tightens the race for adaptive neuro-algorithms.  

Start-ups carve white spaces: Salvia BioElectronics develops bio-electronic foils for migraine, whereas Newronika deploys implantable closed-loop DBS headsets with cloud-based learning loops. Fundraising trends confirm enthusiasm; neurotech ventures raised USD 2.3 billion across 129 deals in 2024, with half directed to Europe-headquartered firms. Component suppliers also feel consolidation pressure as OEMs seek secure rare-earth pipelines and vertically integrate firmware. Competitive intensity is thus forecast to escalate, rewarding players that balance innovation tempo with EU-MDR compliance discipline.

Europe Neurostimulation Devices Industry Leaders

  1. Medtronic PLC

  2. Abbott Laboratories

  3. The Magstim Company Limited

  4. Renishaw PLC

  5. Boston Scientific Corporation

  6. *Disclaimer: Major Players sorted in no particular order
Europe Neurostimulation Devices Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • April 2025: Globus Medical announced its acquisition of Nevro Corp for USD 250 million, merging the HFX spinal cord stimulation suite with Globus Medical’s broader pain platform.
  • January 2025: Medtronic secured CE mark approval for its adaptive deep brain stimulation technology targeting Parkinson’s treatment in European markets.
  • November 2024: Nevro Corp received CE Mark certification for its HFX iQ system, the first cloud-linked, AI-driven high-frequency spinal cord stimulator in Europe.
  • June 2024: Boston Scientific obtained CE mark approval for its deep brain stimulation software upgrade, enhancing clinical programming flexibility.

Table of Contents for Europe Neurostimulation Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Ageing population & neurological disease burden
    • 4.2.2 Escalating demand for minimally-invasive pain therapies
    • 4.2.3 Rapid product upgrades
    • 4.2.4 Home-based TENS/TMS adoption via e-commerce
    • 4.2.5 EU-MDR driven replacement cycle of legacy implants
    • 4.2.6 Opioid-reduction programs boosting neuromodulation uptake
  • 4.3 Market Restraints
    • 4.3.1 Adverse events & explant risks
    • 4.3.2 Lengthy EU-MDR approval timelines
    • 4.3.3 High device cost & patchy reimbursement
    • 4.3.4 Supply-chain pinch in implant-grade rare-earth materials
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porters Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Technology
    • 5.1.1 Internal Neuromodulation
    • 5.1.1.1 Spinal Cord Stimulation (SCS)
    • 5.1.1.2 Deep Brain Stimulation (DBS)
    • 5.1.1.3 Vagus Nerve Stimulation (VNS)
    • 5.1.1.4 Sacral Nerve Stimulation (SNS)
    • 5.1.1.5 Gastric Electrical Stimulation (GES)
    • 5.1.2 External Neuromodulation
    • 5.1.2.1 Transcutaneous Electrical Nerve Stimulation (TENS)
    • 5.1.2.2 Transcranial Magnetic Stimulation (TMS)
    • 5.1.2.3 Respiratory Electrical Stimulation (RES)
  • 5.2 By Application
    • 5.2.1 Pain Management
    • 5.2.2 Parkinson's Disease
    • 5.2.3 Epilepsy
    • 5.2.4 Depression
    • 5.2.5 Dystonia
    • 5.2.6 Others
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centres
    • 5.3.3 Specialty Clinics
    • 5.3.4 Home-care Settings
    • 5.3.5 Others
  • 5.4 By Geography
    • 5.4.1 Germany
    • 5.4.2 United Kingdom
    • 5.4.3 France
    • 5.4.4 Italy
    • 5.4.5 Spain
    • 5.4.6 Rest of Europe

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Strategic Moves
  • 6.3 Market Share Analysis
  • 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.4.1 Medtronic plc
    • 6.4.2 Boston Scientific Corporation
    • 6.4.3 Abbott Laboratories
    • 6.4.4 Nevro Corporation
    • 6.4.5 LivaNova plc
    • 6.4.6 NeuroSigma Inc.
    • 6.4.7 Neuronetics Inc.
    • 6.4.8 The Magstim Company Ltd.
    • 6.4.9 Renishaw plc
    • 6.4.10 Salvia BioElectronics
    • 6.4.11 ElectroCore Inc.
    • 6.4.12 Soterix Medical
    • 6.4.13 Nurotron Biotechnology
    • 6.4.14 Biotronik SE & Co. KG
    • 6.4.15 Otivio AS
    • 6.4.16 Aleva Neurotherapeutics
    • 6.4.17 MicroTransponder Inc.
    • 6.4.18 Pixium Vision
    • 6.4.19 G-Tec Medical Engineering
    • 6.4.20 Synergia Medical SA

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Europe Neurostimulation Devices Market Report Scope

As per the scope of this report, neurostimulation therapies include invasive and noninvasive approaches that involve the application of electrical stimulation, to drive neural function within a circuit. The market is segmented by technology, application, and geography.

By Technology Internal Neuromodulation Spinal Cord Stimulation (SCS)
Deep Brain Stimulation (DBS)
Vagus Nerve Stimulation (VNS)
Sacral Nerve Stimulation (SNS)
Gastric Electrical Stimulation (GES)
External Neuromodulation Transcutaneous Electrical Nerve Stimulation (TENS)
Transcranial Magnetic Stimulation (TMS)
Respiratory Electrical Stimulation (RES)
By Application Pain Management
Parkinson's Disease
Epilepsy
Depression
Dystonia
Others
By End-User Hospitals
Ambulatory Surgical Centres
Specialty Clinics
Home-care Settings
Others
By Geography Germany
United Kingdom
France
Italy
Spain
Rest of Europe
By Technology
Internal Neuromodulation Spinal Cord Stimulation (SCS)
Deep Brain Stimulation (DBS)
Vagus Nerve Stimulation (VNS)
Sacral Nerve Stimulation (SNS)
Gastric Electrical Stimulation (GES)
External Neuromodulation Transcutaneous Electrical Nerve Stimulation (TENS)
Transcranial Magnetic Stimulation (TMS)
Respiratory Electrical Stimulation (RES)
By Application
Pain Management
Parkinson's Disease
Epilepsy
Depression
Dystonia
Others
By End-User
Hospitals
Ambulatory Surgical Centres
Specialty Clinics
Home-care Settings
Others
By Geography
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current Europe Neurostimulation Devices market size and projected growth?

The market is valued at USD 2.79 billion in 2025 and is expected to reach USD 4.76 billion by 2030, representing an 11.28% CAGR.

Which technology segment is expanding fastest?

External neuromodulation technologies, including advanced TMS systems, are forecast to grow at 11.98% CAGR through 2030.

Why is epilepsy therapy gaining momentum in Europe?

AI-supported seizure prediction and broadened reimbursement for vagus nerve stimulation are driving a 12.03% CAGR in epilepsy applications.

How are home-care settings influencing market dynamics?

Patient preference for convenience and reimbursement for tele-monitored devices underpin a 12.11% CAGR in home-care adoption.

What regulatory factors could slow device launches?

Lengthy EU-MDR review timelines and stricter clinical evidence demands can delay market entry by up to a year for new implants.

Which countries represent the largest and fastest-growing markets?

Germany held 29.91% share in 2024, while France is projected as the fastest grower with a 12.32% CAGR to 2030.

Page last updated on: May 21, 2025

Europe Neurostimulation Devices Market Report Snapshots